Viruses are unique infectious agents because they are obligate intracellular parasites. They cannot reproduce on their own; instead, they hijack the machinery of host human cells to make copies of themselves. This biological reality creates a major challenge in pharmacology. While antibacterial drugs can easily target bacterial cell walls or ribosomes that differ greatly from human cells, antiviral drugs must interfere with viral processes without destroying the host cell.
Developing safe antiviral drugs requires finding specific viral enzymes or structures that are different from normal human cell functions. If a drug is too toxic to the virus, it is often too toxic to the patient. Therefore, successful antiviral therapy aims to halt viral replication, reduce the severity or duration of an infection, and prevent transmission to others, while keeping side effects manageable for the mother and fetus in obstetric practice.
To understand how antiviral drugs work, you must look at the steps a virus takes inside the body. The viral life cycle involves several distinct phases, and each phase provides a target for pharmacological intervention:
Most antiviral agents work by mimicking natural building blocks or blocking specific enzymes like reverse transcriptase, protease, or DNA polymerase, halting the replication cycle mid-stream.
Antiviral drugs are grouped based on the specific type of virus they treat and their chemical structure.
Prescribing medication during pregnancy requires balancing the health benefits to the mother against potential risks to the developing fetus. Many antiviral drugs cross the placenta, meaning fetal exposure is a constant consideration.
For conditions like genital herpes outbreaks near term, acyclovir is frequently prescribed because extensive clinical experience shows it is relatively safe during pregnancy. It helps suppress outbreaks and reduces the need for a cesarean section. For seasonal influenza, prompt treatment with oseltamivir is strongly recommended for pregnant women because influenza poses a severe risk of maternal respiratory failure and pregnancy complications.
Midwives must carefully check local protocols and consult obstetric guidelines before administering any systemic antiviral. Lactation safety is equally vital; while some drugs pass into breast milk in small amounts, others are withheld if infant toxicity is a concern.
The management of Human Immunodeficiency Virus (HIV) in pregnant women is one of the greatest success stories in modern public health and midwifery. Antiretroviral therapy (ART) suppresses the viral load in the mother's blood to undetectable levels, which preserves her immune function and almost entirely prevents vertical transmission—passing the virus from mother to child during pregnancy, labor, or breastfeeding.
Current obstetric guidelines mandate lifelong ART for all pregnant women living with HIV, regardless of their CD4 count. Midwives play a central role in promoting adherence, offering psychological support, and coordinating care with pediatric teams. Additionally, newborns receive prophylactic antiretroviral syrups shortly after birth and may be given replacement feeding counseling depending on national guidelines, ensuring the child remains HIV-negative.
Antiviral drugs, while life-saving, frequently cause significant side effects that can discourage patients from taking their medications properly. Common systemic reactions include nausea, vomiting, diarrhea, headache, and fatigue. Intravenous formulations, such as IV acyclovir, can cause phlebitis at the injection site or temporary renal impairment if the patient is dehydrated.
Midwives and nurses managing patients on antivirals must implement key monitoring strategies:
Viral resistance occurs when viruses mutate and change their structure, making standard antiviral drugs ineffective. Because viruses replicate rapidly and make frequent copying errors, resistant strains can emerge quickly if drug pressure is inconsistent. When a patient misses doses or stops treatment prematurely, the drug concentration in the blood drops to levels that allow partially resistant viral mutants to survive and multiply.
Preventing resistance is a primary responsibility for all healthcare providers. Midwives must emphasize absolute adherence to medication schedules, especially in long-term treatments like antiretroviral therapy for HIV. Combination therapies—using multiple drugs that attack different viral targets simultaneously—are also standard practice because it is much harder for a virus to develop multiple mutations at once.